Market Closed -
Nasdaq
04:00:01 2024-06-06 pm EDT
|
5-day change
|
1st Jan Change
|
2.395
USD
|
-1.84%
|
|
-2.64%
|
-25.39%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,167
|
3,541
|
2,126
|
907.1
|
540.2
|
503.2
|
-
|
-
|
Enterprise Value (EV)
1 |
2,636
|
2,713
|
1,317
|
330.6
|
91.47
|
213.7
|
427.4
|
460.6
|
P/E ratio
|
-14.2
x
|
-12.1
x
|
-7.89
x
|
-2.71
x
|
-1.54
x
|
-1.57
x
|
-1.53
x
|
-1.51
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
55.2
x
|
3,733
x
|
5,686
x
|
399
x
|
121
x
|
16.6
x
|
EV / Revenue
|
-
|
-
|
34.2
x
|
1,361
x
|
963
x
|
169
x
|
103
x
|
15.2
x
|
EV / EBITDA
|
-13.3
x
|
-10.8
x
|
-5.37
x
|
-1.03
x
|
-0.29
x
|
-0.83
x
|
-1.5
x
|
-1.33
x
|
EV / FCF
|
-14
x
|
-15
x
|
-6.38
x
|
-1.46
x
|
-0.38
x
|
-0.97
x
|
-1.86
x
|
-2.03
x
|
FCF Yield
|
-7.14%
|
-6.67%
|
-15.7%
|
-68.3%
|
-262%
|
-103%
|
-53.8%
|
-49.3%
|
Price to Book
|
4.17
x
|
3.28
x
|
2.32
x
|
1.36
x
|
1.06
x
|
1.38
x
|
2.06
x
|
-
|
Nbr of stocks (in thousands)
|
121,902
|
140,280
|
142,516
|
144,210
|
168,277
|
208,784
|
-
|
-
|
Reference price
2 |
25.98
|
25.24
|
14.92
|
6.290
|
3.210
|
2.410
|
2.410
|
2.410
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/23/22
|
2/28/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
38.49
|
0.243
|
0.095
|
1.261
|
4.148
|
30.38
|
EBITDA
1 |
-197.6
|
-250.8
|
-245.3
|
-321.2
|
-313.5
|
-257.5
|
-285.5
|
-346.9
|
EBIT
1 |
-202
|
-258.2
|
-255.8
|
-335.4
|
-327.7
|
-283.2
|
-304.3
|
-329.9
|
Operating Margin
|
-
|
-
|
-664.58%
|
-138,044.86%
|
-344,986.32%
|
-22,456.44%
|
-7,335.38%
|
-1,085.85%
|
Earnings before Tax (EBT)
1 |
-184.9
|
-250.2
|
-257
|
-332.6
|
-327.3
|
-271
|
-297.9
|
-312.2
|
Net income
1 |
-184.6
|
-250.2
|
-257
|
-332.6
|
-327.3
|
-273.4
|
-300
|
-317.1
|
Net margin
|
-
|
-
|
-667.74%
|
-136,885.6%
|
-344,489.47%
|
-21,673.77%
|
-7,232.25%
|
-1,043.63%
|
EPS
2 |
-1.830
|
-2.080
|
-1.890
|
-2.320
|
-2.090
|
-1.539
|
-1.572
|
-1.591
|
Free Cash Flow
1 |
-188.1
|
-181.1
|
-206.3
|
-225.7
|
-239.2
|
-219.2
|
-230
|
-227.2
|
FCF margin
|
-
|
-
|
-535.89%
|
-92,884.77%
|
-251,841.05%
|
-17,383.13%
|
-5,544.21%
|
-748.01%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/23/22
|
2/28/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.051
|
0.061
|
0.086
|
0.049
|
0.047
|
0.052
|
0.044
|
0.043
|
0.021
|
0.022
|
0.8951
|
0.0128
|
0.00731
|
0.0146
|
0.0146
|
EBITDA
1 |
-69.65
|
-76.3
|
-72.92
|
-78.63
|
-93.31
|
-95.56
|
-76.88
|
-59.4
|
-81.63
|
-65.95
|
-64.88
|
-64.45
|
-64.05
|
-69.14
|
-69.06
|
EBIT
1 |
-73.89
|
-79.99
|
-76.59
|
-82.49
|
-96.37
|
-99.07
|
-80.52
|
-62.98
|
-85.11
|
-69.5
|
-67.51
|
-70.13
|
-73.84
|
-76.55
|
-77.81
|
Operating Margin
|
-144,888.24%
|
-131,134.43%
|
-89,062.79%
|
-168,344.9%
|
-205,051.06%
|
-190,519.23%
|
-182,995.45%
|
-146,453.49%
|
-405,280.95%
|
-315,927.27%
|
-7,542.36%
|
-549,647.18%
|
-1,010,079.62%
|
-523,593.71%
|
-532,203.83%
|
Earnings before Tax (EBT)
1 |
-74.87
|
-79.85
|
-74.79
|
-83.15
|
-94.85
|
-98.7
|
-77.99
|
-61.32
|
-85.78
|
-65
|
-65.48
|
-68.07
|
-71.92
|
-75.11
|
-76.35
|
Net income
1 |
-74.87
|
-79.85
|
-74.79
|
-83.15
|
-94.85
|
-98.7
|
-77.99
|
-61.32
|
-85.78
|
-65
|
-65.9
|
-68.49
|
-72.26
|
-75.11
|
-76.35
|
Net margin
|
-146,800%
|
-130,901.64%
|
-86,961.63%
|
-169,689.8%
|
-201,802.13%
|
-189,815.38%
|
-177,247.73%
|
-142,593.02%
|
-408,466.67%
|
-295,454.55%
|
-7,361.61%
|
-536,748.12%
|
-988,512.31%
|
-513,730.03%
|
-522,219.56%
|
EPS
2 |
-0.5400
|
-0.5600
|
-0.5200
|
-0.5800
|
-0.6600
|
-0.6800
|
-0.5300
|
-0.3700
|
-0.5100
|
-0.3800
|
-0.3508
|
-0.3529
|
-0.3696
|
-0.3862
|
-0.3762
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/23/22
|
5/4/22
|
8/9/22
|
11/2/22
|
2/28/23
|
5/3/23
|
8/2/23
|
11/2/23
|
3/14/24
|
5/13/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
531
|
828
|
809
|
576
|
449
|
289
|
75.8
|
42.6
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-188
|
-181
|
-206
|
-226
|
-239
|
-219
|
-230
|
-227
|
ROE (net income / shareholders' equity)
|
-27.7%
|
-29.3%
|
-25.8%
|
-42%
|
-55.5%
|
-67.6%
|
-78.5%
|
-
|
ROA (Net income/ Total Assets)
|
-24.8%
|
-25.7%
|
-22.7%
|
-35.8%
|
-44.7%
|
-51.8%
|
-61.2%
|
-
|
Assets
1 |
745.8
|
972.8
|
1,133
|
927.9
|
732.2
|
528
|
489.9
|
-
|
Book Value Per Share
2 |
6.220
|
7.690
|
6.430
|
4.610
|
3.040
|
1.740
|
1.170
|
-
|
Cash Flow per Share
|
-
|
-0.9600
|
-1.360
|
-1.540
|
-
|
-
|
-
|
-
|
Capex
1 |
50.8
|
66
|
21.4
|
5.19
|
1.52
|
3.54
|
3.14
|
5.86
|
Capex / Sales
|
-
|
-
|
55.72%
|
2,136.21%
|
1,595.79%
|
280.8%
|
75.81%
|
19.28%
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/23/22
|
2/28/23
|
3/14/24
|
-
|
-
|
-
|
Last Close Price
2.395
USD Average target price
11.32
USD Spread / Average Target +372.46% Consensus |
1st Jan change
|
Capi.
|
---|
| -25.39% | 509M | | +19.33% | 125B | | +13.95% | 109B | | -3.53% | 24.74B | | +2.71% | 22.67B | | -9.95% | 18.14B | | -41.48% | 16.67B | | -12.62% | 16.64B | | +0.99% | 13.45B | | +21.79% | 11.32B |
Bio Therapeutic Drugs
|